Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2025-2744

Published: 2025

Journal Articles

Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP

Blood (2025) 146 (Supplement 1): 6395.

https://doi.org/10.1182/blood-2025-6395

Published: 2025

Journal Articles

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Blood (2025) 146 (Supplement 1): 881.

https://doi.org/10.1182/blood-2025-881

Published: 2025

Journal Articles

Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT.

Blood (2025) 146 (Supplement 1): 1059.

https://doi.org/10.1182/blood-2025-1059

Published: 2025

Journal Articles

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

Blood (2025) 146 (Supplement 1): 1427.

https://doi.org/10.1182/blood-2025-1427

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Blood (2025) 146 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2025-1842

Published: 2025

Journal Articles

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Blood (2025) 146 (Supplement 1): 4521.

https://doi.org/10.1182/blood-2025-4521

Published: 2025

Journal Articles

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

Anne Huynh, Romain Buono, Edouard Forcade, Hélène Labussière, Patrice Ceballos, Jerome Cornillon, Quentin Cabrera, Maud D'Aveni, Amine Belhabri, Marie Robin, Raynier Devillier, Nicole Raus, Mauricette Michallet

Blood (2025) 146 (Supplement 1): 4297.

https://doi.org/10.1182/blood-2025-4297

Published: 2025

Journal Articles

Prognostic analysis of salvage allogeneic HCT in acute leukemia patients relapsing after autologous HCT: a study from the acute leukemia working party of the EBMT

Blood (2025) 146 (Supplement 1): 6041.

https://doi.org/10.1182/blood-2025-6041

Published: 2025

Journal Articles

Salvage-free, transplantation-free survival (STFS) in AML: Proposition for a novel clinical endpoint to better assess the efficacy of novel drugs in combination with intensive chemotherapy. a dataml registry study.

Christian Recher, Emilie Bérard, Suzanne Tavitian, Thibaut Leguay, Anne Huynh, Edouard Forcade, Alban Canali, Emilie Klein, Audrey Bidet, Eric Delabesse, Véronique De Mas, Audrey Sarry, Madeline Mougenot, Anne Charlotte De Grande, Arnaud Pigneux, Sarah Bertoli, Pierre-Yves Dumas

Blood (2025) 146 (Supplement 1): 450.

https://doi.org/10.1182/blood-2025-450

Published: 2025

Journal Articles

Post-transplant cyclophosphamide (PTCy) versus other graft-versus-host disease prophylaxis strategies in reduced intensity allogeneic stem cell transplantation from related and matched unrelated donors in patients with acute myeloid leukemia and myelodysplastic syndromes: A study from the french society of bone marrow transplantation (SFGM-TC) registry

Blood (2025) 146 (Supplement 1): 2450.

https://doi.org/10.1182/blood-2025-2450

Published: 2025

Journal Articles

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2025-4288

Published: 2025

Journal Articles

Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trial

Blood (2025) 146 (Supplement 1): 26.

https://doi.org/10.1182/blood-2025-26

Published: 2025

Journal Articles

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3

Blood blood.2025029734.

https://doi.org/10.1182/blood.2025029734

Published: 2025

Includes: Supplemental data

Journal Articles

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 851.

https://doi.org/10.1182/blood-2024-201380

Published: 2024

Journal Articles

Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Arnon Nagler, Allain-Thibeault Ferhat, Nicolaus Kröger, Matthias Eder, Gerard Socie, Didier Blaise, Thomas Schroeder, Hélène Labussière-Wallet, Johan Maertens, Alessandro Busca, Edouard Forcade, Tobias Gedde-Dahl, Alessandro Rambaldi, Claude-Éric Bulabois, Fabio Ciceri, Mohamad Mohty

Blood (2024) 144 (Supplement 1): 505.

https://doi.org/10.1182/blood-2024-194057

Published: 2024

Journal Articles

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Antonio M Risitano, Simona Iacobelli, Austin G. Kulasekararaj, Marleen Van Os, Sophie Terwel, Morag Griffin, Constantijn J.M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Carlos Vallejo, Beatrice Drexler, Jean-Baptiste Méar, Alexander Smith, Emanuele Angelucci, Reinier Raymakers, Marco R De Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda Balari, Isabel Sanchez-Ortega, Blanca Xicoy, Isidro Jarque Ramos, Jamie Cavenagh, Flore Sicre De Fontbrune, Camilla Frieri, Talha Munir, Jennifer Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob Passweg, Sr., Judith Marsh, Gerard Socie, Ghulam Mufti, Carlo Dufour, Regis Peffault De Latour

Blood (2024) 144 (Supplement 1): 302.

https://doi.org/10.1182/blood-2024-194699

Published: 2024

Journal Articles

Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study

Blood (2024) 144 (Supplement 1): 596.

https://doi.org/10.1182/blood-2024-194780

Published: 2024

Journal Articles

Recursive Partitioning As a Tool for Differential Diagnosis between Acquired and Inherited Bone Marrow Failure Syndromes (BMF)

Eléonore Kaphan, Anouk Walter Petrich, Lise Larcher, Thierry Leblanc, Mony Fahd, Benedicte Bruno, Edouard Forcade, Cecile Renard, Arthur Sterin, Michael Loschi, Elodie Lainey, Jean Soulier, Caroline Kannengiesser, Gerard Socie, Regis Peffault De Latour, Jerome Lambert, Flore Sicre de Fontbrune

Blood (2024) 144 (Supplement 1): 1314.

https://doi.org/10.1182/blood-2024-201084

Published: 2024

Journal Articles

Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Blood (2024) 144 (Supplement 1): 4909.

https://doi.org/10.1182/blood-2024-203964

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party

Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP

Randomized study of high-dose cytarabine with or without dexamethasone as post-remission therapy in younger adults with newly diagnosed AML – the french backbone intergroup (BIG)-1 study on behalf of the filo, ALFA, and SFGM-TC study groups

Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT.

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Impact on overall and progression-free survivals of iron chelation given 6 months after allogeneic hematopoietic stem cell transplantation for Acute Myeloid Leukemia and myelodysplastic syndrom

Prognostic analysis of salvage allogeneic HCT in acute leukemia patients relapsing after autologous HCT: a study from the acute leukemia working party of the EBMT

Salvage-free, transplantation-free survival (STFS) in AML: Proposition for a novel clinical endpoint to better assess the efficacy of novel drugs in combination with intensive chemotherapy. a dataml registry study.

Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT

Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trial

Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 Cohort 3

Challenging the Adverse Label: Diverse Outcomes of ELN 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation in First Remission: On Behalf of the EBMT Acute Leukemia Working Party

Non-T-Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation from Unrelated and Matched Sibling Donors in Patients with Secondary Acute Myeloid Leukemia in First Complete Remission: A Study from the ALWP/EBMT

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Long-Term Outcome of Unrelated Cord Blood Transplantation in Patients with Idiopathic Refractory Severe Aplastic Anemia: A Nationwide Phase 2 Study

Recursive Partitioning As a Tool for Differential Diagnosis between Acquired and Inherited Bone Marrow Failure Syndromes (BMF)

Cyclosporine Versus Cyclosporine Plus Mycophenolate Mofetil in Reduced Intensity Allogeneic Stem Cell Transplantation for Intermediate-Risk AML: A Multi-Center Randomized Study from the Acute Leukemia French Intergroup, on Behalf of the Filo, ALFA, and SFGM-TC Study Groups

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only